60 DEGREES PHARMACEUTICALS, INC.

Listed Company

SXTPWCIK 0001946563NasdaqEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$1.01M

Net Income

$-7.37M

Total Assets

$5.37M

Equity

$3.46M

Shares Out

2.64M

Op. Cash Flow

$-6.85M

Business

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company developing and commercializing therapies to prevent and treat infectious diseases. Its main products and programs center on Arakoda (tafenoquine) for malaria prevention and repositioning tafenoquine for babesiosis and fungal infections, plus development of antiviral candidate celgosivir. Key business activities include commercialization of approved products, clinical development programs, and licensing/collaboration arrangements. The company markets and distributes products in the United States, Australia and select ex-U.S. territories through distributors and specialty pharmacy channels.

Summary from filing dated 2025-03-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Product Revenues net of Discounts and Rebates	1	607,574	253,573	223,208
Cost of Revenues	781,695	384,765	474,550	432,370
Gross Profit	223,776	222,809	−220,977	−209,162
Research Revenues	403,624	73,771	—	288,002
Net Revenue	627,400	296,580	−220,977	—
Research and Development	2	5	691,770	525,563
General and Administrative Expenses	6	5	4	1
Total Operating Expenses	8	10	5	2
Loss from Operations	−8	−10	−5	−2
Interest Expense	−7,805	−7,912	−2	—
Change in Fair Value of Derivative Liabilities	266,089	2	—	—
Other Income, net	131,970	101,464	−83,116	−43,238
Total Interest and Other Income (Expense), net	390,254	2	—	—
Loss from Operations before Provision for Income Taxes	−7	−8	−4	−6
Provision for Income Taxes (Note 9)	0	0	250	500
Net Loss including Noncontrolling Interest	−7	−8	−4	−6
Net Loss Noncontrolling Interest	−3,167	−8,556	−48,098	3,936
Net Loss attributed to 60 Degrees Pharmaceuticals, Inc.	−7	−8	−4	−6
Unrealized Foreign Currency Translation Gain (Loss)	7,127	−90	61,853	—
Total Comprehensive Loss	−7	−8	−4	−6
Net Loss Noncontrolling Interest	−3,167	−8,556	−48,098	—
Comprehensive Loss attributed to 60 Degrees Pharmaceuticals, Inc.	−7	−8	−4	−6
Cumulative Dividends on Series A Preferred Stock	−501,056	−483,301	−220,714	—
Net Loss - attributed to common stockholders	−8	−8	−4	−6
Basic (in Dollars per share)	−11.73	−74.17	−59.18	−2.61
Diluted (in Dollars per share)	−11.73	−74.17	−59.18	−2.61
Basic (in Shares)	670,211	113,665	66,314	2
Diluted (in Shares)	670,211	113,665	66,314	2

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and Cash Equivalents	2	2	2	—	—
Accounts Receivable	509,644	486,748	231,332	45,965	—
Prepaid and Other Assets	978,131	1	4	—	—
Short-Term Investments	1	2	—	—	—
Inventory (Note 3)	656,924	442,764	466,169	518,578	—
Total Current Assets	5	5	7	1	—
Property and Equipment, net (Note 4)	246,365	149,808	57,761	21,300	—
Long-Term Prepaid Expense	0	66,176	242,647	—	—
Intangible Assets, net (Note 5)	224,361	157,084	227,258	164,255	—
Total Other Assets	224,361	223,260	483,422	—	—
Total Assets	5	6	8	1	—
Accounts Payable and Accrued Expenses	1	1	506,206	758,668	—
SBA EIDL (including accrued interest) (Note 7)	8,772	8,772	—	—	—
Derivative Liabilities (Note 8)	374,741	640,830	2	1	—
Total Current Liabilities	2	2	3	24	—
SBA EIDL (including accrued interest) (Note 7)	144,003	147,119	—	—	—
Total Long-Term Liabilities	144,003	147,119	150,251	2	—
Total Liabilities	2	2	3	25	—
Commitments and Contingencies (Note 11)	—	—	—	—	—
Series A Preferred Stock, $0.0001 par value, 1,000,000 shares authorized; 76,480 and 76,480 issued and outstanding as of December 31, 2025 and December 31, 2024, respectively (Note 6)	10	10	10	—	—
Common Stock, $0.0001 par value, 150,000,000 shares authorized; 1,163,142 and 141,749 issued and outstanding as of December 31, 2025 and December 31, 2024, respectively(1) (Note 6)	116	14	10	239	—
Additional Paid-in Capital	42	35	27	5	—
Accumulated Other Comprehensive Income	142,598	135,471	135,561	73,708	—
Accumulated Deficit	−48	−41	−33	−29	—
60P Shareholders Equity:	3	4	5	−24	—
Noncontrolling Interest	−83,761	−80,594	−72,038	−572,320	—
Total Shareholders Equity	3	4	5	−24	−18
Total Liabilities and Shareholders Equity	5	6	8	1	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Depreciation	43,324	11,726	21,162	27,648
Amortization	39,548	38,502	29,157	5,118
Amortization of ROU Asset	0	13,517	50,053	—
Amortization of Capitalized Share-Based Payments	176,471	4	994,643	—
Share-Based Compensation under Equity Incentive Plan	279,873	32,767	528,926	—
Change in Fair Value of Derivative Liabilities	−266,089	−2	37,278	—
Write-offs of Capitalized Patents	0	108,424	—	—
Change in Inventory Reserve	251,677	0	—	—
Accounts Receivable	−22,896	−255,416	−185,367	100,397
Prepaid and Other Assets	−19,486	−39,423	−522,370	24,902
Inventory	−465,837	23,405	212,747	10,126
Accounts Payable and Accrued Liabilities	491,083	501,412	−214,734	169,990
Accrued Interest, net	11,635	−23,604	1	3
Reduction of Lease Liability	0	−13,650	−50,273	−46,795
Net Cash Used in Operating Activities	−7	−6	−5	−1
Capitalization of Patents	−55,533	−51,967	−39,982	—
Purchases of Fixed Assets	−139,881	−103,773	−57,623	—
Acquisition of Intangibles	−22,670	−25,374	−18,283	−27,070
Purchase of Short-Term Investments	−1	−2	—	—
Maturities of Short-Term Investments	2	0	—	—
Net Cash Provided by (Used in) Investing Activities	254,916	−2	−115,888	−60,133
Net Proceeds from January 2024 Offering	0	2	—	—
Net Proceeds from January 2025 Offering	804,346	0	—	—
Net Proceeds from February 2025 Offering	908,627	0	—	—
Net Proceeds From July 2025 Offering	4	0	—	—
Shares Withheld for Net Share Settlement of Performance Bonuses	−18,000	0	—	—
Net proceeds from ATM Offering	458,614	2	—	—
Net proceeds from Private Placement	0	3	—	—
Proceeds from Exercise of Pre-Funded Warrants	2,804	10,963	—	—
Net Cash Provided by Financing Activities	6	7	6	1
Effect of Exchange Rate Changes on Cash	7,127	499	61,853	—
Change in Cash and Cash Equivalents	−149,288	−483,132	2	149,466
Cash paid During the Year for Interest	8,772	8,772	179,117	2,193
Cash paid During the Year for Income Taxes	0	0	1,000	1,000
Conversion of Series A Preferred Stock into Common Stock	0	290,601	270,460	—
Capitalized Share-Based Payments to Vendors	0	26,325	5	—
Fair Value of Warrants Issued to Underwriters	0	71,364	301,416	—
Capitalized Patent Costs included in Accounts Payable	24,292	0	33,895	—
Capitalized Website Costs included in Accounts Payable	4,330	0	—	—
ATM Offering Costs included in Accounts Payable	53,500	0	—	—
Gross Shares Issued for Annual Performance Bonuses	121,544	0	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro